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Human Papillomavirus Infection and Cervical Dysplasia
in a Subset of Arab American Women
Anita Shallal,1,i Evi Abada,2,ii Ziad Fehmi,3 Saivaishnavi Kamatham,4 Joseph Trak,4 Omar Fehmi,3
Andrew Toma,5 Sarah Farooqi,4,iii Hyejeong Jang,6 Seongho Kim,6 Sudeshna Bandyopadhyay,2
Marcus Zervos,1 and Rouba Ali-Fehmi2,*,iv
Abstract
Background: With limited health data on Arab Americans (AAs), we sought to describe the health-seeking
behaviors, prevalence of abnormal cervical cytology and high-risk human papillomavirus (HPV) serotypes, and
the relationship with socioeconomic factors among a subset of AA women.
Methods: Retrospective observational cohort study of women undergoing routine cancer screening at the ArabAmerican Center for Economic and Social Services clinic. Data collected included demographics, tobacco use, gross
monthly income, prior Papanicolaou (Pap) smear history, and results of cervical cytology and high-risk HPV testing.
Results: Of 430 women, 74 (17%) reported that they had never had a Pap smear. Three hundred eighty-eight (90%)
women had cervical cytology interpreted as ‘ negative for intraepithelial lesion,’’ the remaining 42 (10%) women had
abnormal results. Thirteen (3%) women reported prior abnormal Pap smear, which was signiﬁcantly associated with
additional abnormal Pap smear on multivariable analyses (odds ratio 65.46; 95% conﬁdence interval [CI] 17.01–
338.62; p < 0.001). One hundred twenty-ﬁve (29%) women were tested for high-risk HPV serotypes; 106 (91%) had negative results, 4 (3%) were positive for HPV-16, 7 (6%) were positive for other high-risk serotypes, and 8 results were not
recorded. A negative HPV screen was signiﬁcantly associated with a negative Pap smear (Fisher’s exact test p = 0.006).
There was no signiﬁcant association between abnormal cervical cytology and evaluated socioeconomic factors.
Conclusions: Additional population based-studies to determine cervical dysplasia/cancer and HPV prevalence in
women of Middle Eastern descent are needed.
Keywords: HPV; Arab American women; cervical cancer screening; Pap smear; cervical dysplasia

Background
It is estimated that cervical cancer is the second most
common cause of cancer among women worldwide,
and 80% of cases occur in developing countries.1–3
Persistent infection with human papillomavirus

(HPV), a sexually transmitted infection, is known to
be the primary cause of cervical cancer. Majority of
cases are squamous cell carcinoma, followed by adenocarcinomas. The Papanicolaou (Pap) smear, a
screening examination that detects abnormal cells in
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the cervix, is the single most effective tool available for
early diagnosis and treatment of cervical cancer. The
test can also be used to assess for the presence of
high-risk oncogenic HPV strains (in particular,
strains 16 and 18).4
Strong evidence supports the beneﬁts of early detection in substantially reducing cervical cancer incidence
and mortality. Therefore, deaths from cervical cancer
can be used as a marker of health care inequity and inability to access health care. Despite the effectiveness of
these screening strategies, signiﬁcant racial and ethnic
disparities in cervical cancer screening and detection
still exists worldwide. These disparities are related to
multiple intersecting factors, including race, ethnicity,
culture, socioeconomic status, immigration status, religion, and nativity (country of citizenship at birth),
which may inﬂuence an individual’s ability to receive
preventative care.5
In Middle Eastern countries, the Pap smear is less
utilized, and organized screening programs for cervical
cancer is limited.6 This results in a large percentage of
women who are under or never screened.7 As a result,
mortality rates for cervical cancer in the Middle East
are disproportionately high when compared with developed countries, and the majority of cases are diagnosed at later stages.7 The mortality rates reﬂect barriers
to assessing regular screening, including lack of health
insurance, length of stay in the United States, lack of
transportation or childcare, as well as costs of health
care.7 Personal factors such as language barriers, lack
of knowledge about importance of screening, as well
as fear of pain or embarrassment from a male provider
may also result in reduced screening.3,8 Cultural and
religious beliefs are also barriers to screening, as one
study revealed that single Arab women may not seek
out gynecologic examinations or HPV vaccination due
to fear of stigmatization.5
In light of the aforementioned, data on cervical
cancer screening for Arab American (AA) women
are signiﬁcantly limited. The Arab-American
Center for Economic and Social Services (ACCESS)
clinic is the largest and most comprehensive Arab
community-based health and mental health center
in North America and is considered a ‘‘one stop service center’’ for medical, public health, mental
health, and environmental programs for this particular community.9 ACCESS provides culturally sensitive and community-centered health care services to
AA in Southeast Michigan. The aim of this study was
to evaluate the health-seeking behaviors surround-
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ing Pap smears, describe the prevalence of abnormal
cervical cytology and high-risk HPV serotypes, and
ﬁnally, to correlate the relationship between abnormal cervical cytology results and socioeconomic factors in this subset of AA women who received care at
the ACCESS clinic.
Methods
This retrospective observational cohort study was
approved by the Wayne State University and the
Henry Ford Health System Institutional Review
Boards. We reviewed clinical records of AA women
who presented for routine cancer screening as part
of the Breast and Cervical Cancer Control Program
(BCCCP) at the ACCESS Clinic in southeast Michigan. AA women include women with origins from
the ‘‘Arab World’’ who have immigrated to and
now reside in the United States. The ‘‘Arab World’’
includes 22 countries namely, Algeria, Bahrain, the
Comoros Islands, Djibouti, Egypt, Iraq, Jordan,
Kuwait, Lebanon, Libya, Morocco, Mauritania,
Oman, Palestine, Qatar, Saudi Arabia, Somalia,
Sudan, Syria, Tunisia, the United Arab Emirates,
and Yemen. Medical records for these women were
reviewed for information, including age, date of
birth, gross monthly income, history of tobacco
use, prior Pap smear history, including those who declined a Pap smear test, cervical cytology results, and
high-risk HPV testing results. Gross monthly incomes were stratiﬁed into those earning <$2000
U.S. dollars (USD) and ‡$2000 USD per month.
AA women who presented for care at the ACCESS
clinic between 2003 and 2019 and who were between
the ages of 21 and 65 years at the time of their visit
were included in the study. Women who had a prior
hysterectomy with removal of the cervix were excluded.
All collected data were deidentiﬁed. In instances where
cytology was performed, results were documented as
unsatisfactory sample, negative for intraepithelial lesion, atypical cells of undetermined signiﬁcance, atypical squamous cells cannot rule out high-grade
squamous intraepithelial lesion, low-grade squamous
intraepithelial lesion, high-grade squamous intraepithelial lesion, and atypical glandular cells. In instances
where high-risk HPV testing was performed, negative
results were documented as negative, and positive results were documented as positive for HPV 16, 18, or
other high-risk strains (31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 66, and 68) or unavailable if serotype testing result was not recorded.
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Statistical analysis
Patient characteristics were summarized by count and
percentage for categorical variables and median and
range for continuous variables. Fisher’s exact tests
and Wilcoxon rank-sum tests were used to compare
categorical and continuous variables, respectively, between groups. Univariable and multivariable logistic
regression analyses were performed to assess associations between ﬁve patient baseline characteristics
(age, monthly income, tobacco use, never had Pap,
and prior abnormal Pap) and cervical cytology (abnormal vs. normal, with normal as reference). In particular, Firth logistic regression models were used to
reduce bias in maximum likelihood estimation caused
by rare events. The association between cervical cytology and high-risk HPV was assessed by Fisher’s exact
tests.
Results
A total of 464 charts from the BCCCP program were
reviewed. Thirty-four cases with unavailable cervical
cytology results were excluded from the analysis. Four
hundred thirty women were included in the study. All
women were uninsured and had immigrated from Middle Eastern countries, including Yemen and Lebanon.
The average age of the women was 49 years (range
23–65). Women with abnormala Pap smears were signiﬁcantly more likely to be younger in age (Wilcoxon
rank-sum test p = 0.022). A summary of patient characteristics is presented in Table 1. Seventy-four (17%)
women reported that they had never had a prior Pap
smear. However, not having a previous Pap smear
had no association with having an abnormal Pap
smear at the BCCCP on univariable (odds ratio
[OR] = 0.66; 95% conﬁdence interval [CI] 0.23–1.59;
p = 0.377) and multivariable (OR = 1.81; 95% CI 0.48–
5.71; p = 0.355) analyses (Table 2). A total of 388
(90%) women had cervical cytology interpreted as
‘‘negative for intraepithelial lesion’’ at the BCCP. The
remaining 42 (10%) women had abnormal cervical cytology results. Thirteen (3%) women reported prior abnormal Pap smear results before coming to the BCCCP
and this was statistically signiﬁcant with having another abnormal Pap smear on both univariable
(OR = 47.74; 95% CI 14.06–203.85; p < 0.001) and multivariable analyses (OR = 65.46; 95% CI 17.01–338.62;
a

Abnormal cervical cytology (Pap smear) results recorded include; [atypical cells of
undetermined signiﬁcance, atypical squamous cells cannot rule out high grade
squamous intraepithelial lesion, low grade squamous intraepithelial lesion, high
grade squamous intraepithelial lesion, and atypical glandular cells.

275

Table 1. Patient Characteristics
Cervical cytology
Variable

All
(n = 430)

Normala
(n = 388)

Abnormalb
(n = 42)

pb

49 (23–65)

49 (23–65)

47 (30–59)

0.022

Age, years,
median (range)
Monthly income,
n (%)
<$2000
‡$2000
Unknown

321 (75)
105 (24)
4 (1)

287 (74)
98 (25)
3 (1)

34 (81)
7 (17)
1 (2)

Tobacco use, n (%)
Yes
No
Unknown

86 (20)
323 (75)
21 (5)

79 (20)
290 (75)
19 (5)

7 (17)
33 (79)
2 (5)

69 (18)
264 (68)
55 (14)

5 (12)
31 (74)
6 (14)

0.340

0.685

Never had Pap, n (%)
Yes
74 (17)
No
295 (69)
Unknown
61 (14)
Prior abnormal Pap
smear, n (%)
Yes
13 (3)
No
295 (69)
Unknown
122 (28)
HPV testing done,
n (%)
Yes
No
Unknown

0.389

<0.001
3 (1)
278 (72)
107 (28)

10 (24)
17 (40)
15 (36)
<0.001

125 (29)
263 (61)
42 (10)

89 (23)
259 (67)
40 (10)

36 (86)
4 (10)
2 (5)

a

Negative for intraepithelial lesion.
ASC-US (atypical cells of undetermined signiﬁcance), ASC-H (atypical
squamous cells cannot rule out high-grade squamous intraepithelial
lesion), LSIL (low-grade squamous intraepithelial lesion), HSIL (highgrade squamous intraepithelial lesion), and AGC (atypical glandular
cells).
c
Fisher’s exact test or Wilcoxon rank-sum test as appropriate.
HPV, human papillomavirus; Pap, Papanicolaou.
b

p < 0.001) (Table 2). One hundred twenty-ﬁve (29%)
women were tested for high-risk HPV serotypes. Of
these, 106 (91%) had negative results, 4 (3%) were positive for HPV 16, 7 (6%) were positive for other highrisk HPV serotypes, and 8 results were not recorded.
Having a negative HPV screen was signiﬁcantly associated with having a negative Pap smear (Fisher’s exact
test p = 0.006; Table 3). Three hundred twenty-one
(75%) women had a gross monthly income <$2000
USD. Eighty-six (20%) women reported using tobacco.
However, having a gross monthly income <$2000 USD
(OR = 0.43; 95% CI 0.10–1.36; p = 0.162) and history of
tobacco use (OR = 0.72; 95% CI 0.16–2.40; p = 0.611)
had no association with having an abnormal cervical
Pap smear result (Table 2).
Discussion
Population-based screening programs have resulted in
minimizing mortality and morbidity from cervical
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Table 2. Univariable and Multivariable Logistic Regression Analyses of Risk Factors Associated with Cervical Cytology
(Abnormal vs. Normal, with Normal as Reference)
Univariablea
Event/n

OR (95% CI)

Multivariablea
p

Event/n

OR (95% CI)

p

Age
Monthly income
<$2000
‡$2000

42/430

0.96 (0.93–1.00)

0.050

25/296

0.94 (0.88–1.01)

0.104

34/321
7/105

Ref.
0.63 (0.26–1.37)

0.259

19/221
6/75

Ref.
0.43 (0.10–1.36)

0.162

Tobacco use
No
Yes

33/323
7/86

Ref.
0.82 (0.33–1.78)

0.629

22/231
3/65

Ref.
0.72 (0.16–2.40)

0.611

Never had Pap
No
Yes

31/295
5/74

Ref.
0.66 (0.23–1.59)

0.377

21/253
4/43

Ref.
1.81 (0.48–5.71)

0.355

<0.001

15/283
10/13

Prior abnormal Pap
No
17/295
Yes
10/13

Ref.
47.74 (14.06–203.85)

Ref.
65.46 (17.01–338.62)

<0.001

Event/n, numbers of events (abnormal) and patients.
a
Univariable and multivariable Firth logistic regression analyses, respectively.
CI, conﬁdence interval; OR, odds ratio; Ref., reference.

cancer.6 AA are a rapidly growing ethnic minority in
the United States with a growth rate of 72% from
2000 to 2010.5 They are also particularly understudied
with regard to preventive health behaviors, in part because this population is classiﬁed as ‘‘White’’ by the
U.S. government, leaving them overlooked, and rendering them effectively invisible as an ethnic minority,
and also leading to a lack of research being conducted
with this population.5 Recently emigrated AA women
are vulnerably situated at an intersection of race, ethnicity, socioeconomic status, culture, and religion.
These women, who were already less likely to undergo
screening in their home country before immigrating to
the United States,7 may continue to decline screening
even when it is offered, particularly given the cultural
stigma associated with sexually transmitted infections.
This behavior is evident in our results, where 17% of
the participants had never undergone a Pap smear,

compared with *6.8% of U.S. women.10 A secondary
data analysis of the 2000–2011 National Health Interview Survey (NHIS) compared cancer screening behaviors of U.S.-born and foreign-born (European and
Arab countries) non-Hispanic white women. After
adjusting for age, foreign-born AA women were significantly less likely (84%) to receive a Pap test in their
lifetime than European (87%) and U.S. (95%) women
( p £ 0.00).11
According to the Centers for Disease Control and
Prevention, risk factors for cervical cancer development include absence of cervical cancer screening, history of persistent infection with HPV, increasing
number of lifetime sexual partners, early age of sexual
activity, as well as history of other sexually transmitted
infections, such as herpes simplex virus and Chlamydia
trachomatis.4 In addition, a growing number of studies
have shown that tobacco use may be an additional risk

Table 3. Association Between Cervical Cytology and High-Risk Human Papillomavirus Among Patients
Who Had Human Papillomavirus Testing
Cervical cytologya
High risk HPV
Negative
Positive for HPV 16
Positive for other high-risk HPVc
Unknown
a

NIL (n = 89)

ASC-US (n = 29)

ASC-H (n = 2)

LSIL (n = 5)

Total (N = 125)

pb

81 (95%)
2 (2%)
2 (2%)
4

22 (85%)
1 (4%)
3 (12%)
3

1 (50%)
0 (0%)
1 (50%)
0

2 (50%)
1 (25%)
1 (25%)
1

106 (91%)
4 (3%)
7 (6%)
8

0.006

The Bethesda System, 2001.
Fisher’s exact test.
c
Other serotypes: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
b
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factor, with a dose–response relationship between tobacco use and cervical cancer.12,13 Although tobacco
use is decreasing slowly in the United States, there remains a high prevalence of tobacco use within Middle
Eastern countries.14 Within our study population, 20%
of the women reported tobacco use. However, the use
of tobacco was not signiﬁcantly associated with abnormal cervical cytology in our study ( p = 0.611; Table 2).
In comparison, according to recent statistics, among
factors contributing to cervical cancer, women in the
United States had a smoking prevalence of 15.9%.15
Living in poverty is also a well-established risk factor
for the development of cervical cancer.16 Our results
indicate that most (75%) of the AA women in this
study recorded making a gross monthly income <$2000
USD. However, a gross monthly income <$2000 USD
was not signiﬁcantly associated with abnormal cervical
cytology ( p = 0.162; Table 2). In contrast, data from
the surveillance, epidemiology, and end results (SEER)
study show that a lower socioeconomic status was associated with a risk of developing cervical cancer in U.S.
women.17
Abnormal cervical Pap smears with an interpretation of atypical cells of undetermined signiﬁcance or
higher was seen in 42 (10%) of the women seen at the
ACCESS clinic. Of these, high-grade squamous
intraepithelial lesion/severe dysplasia and atypical
glandular cells were seen in <1% of the women. No
invasive carcinomas (squamous or glandular) were
detected in this subset of women. High-risk HPV
strains were detected in only 11 (9%) of the women
with abnormal cervical cytology among those 125
women who were tested for HPV (Table 3). Of
note is that HPV 18 serotypes were not detected in
this subset of AA women who recently immigrated
to the United States, whereas HPV 16 and other
high-risk serotypes were variably detected. In comparison, results from a large U.S. screening population
data indicates that HPV 16 genotype was more prevalent in women of all age groups.18 Serotype prevalence
has been studied in other populations, from South
America to East Asia.19 HPV genotype 16 and 18
have been identiﬁed as the predominant oncogenic
types, causing *70% of all cervical cancer cases worldwide.20 However, there is limited to no data on seroprevalence across the Middle East. To our knowledge, this
study is the ﬁrst of its kind to look at seroprevalence
among a subset of AA women who recently immigrated to the U.S. population-based studies to determine which serotypes are more common among this
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ethnicity are encouraged, as such knowledge may
play a role in vaccine development and treatment. In
addition, out of the 125 women from our study population tested for high-risk HPV serotypes, 106 (91%)
had negative results. Nonetheless, having a negative
HPV screen was signiﬁcantly associated with having
a negative Pap smear (Fisher’s exact test p = 0.006;
Table3). Our ﬁndings are consistent with what has
been previously reported from a U.S.-based study, in
which a negative HPV screen was correlated with a
negative Pap smear result.21
Finally, given the prior literature on the rates of cervical cancer in Middle Eastern countries (particularly
low-income countries), we anticipated identifying a
higher rate of cervical dysplasia, as well as cervical
cancer within our study cohort. However, this is not
what was identiﬁed, and in fact, no cases of cervical
cancer were diagnosed in our cohort. In comparison,
the review by Islami et al. found that among nonHispanic whites, the overall incidence rate of histologically conﬁrmed cervical cancer decreased by 1.1%
per year from 2003 to 2013; with rates stabilizing
afterward (from 2013 to 2015).22 This ﬁnding of
decreasing incidence in cervical cancer cases among
non-Hispanic white women can be attributed to the
effectiveness of cervical screening programs in the
United States. We wish to note that cervical cancer
screening is a well-established program within highincome countries such as the United States, where our
study participants currently live.
Study limitations
It is important to note that there are a number of limitations to this study. First, the retrospective nature of the
study limits the available data and statistics. Next, as the
medical records were all paper, issues encountered included lost sheets of paper without backup copies, illegible notes, or incomplete information. All attempts were
made to collect the data without inference and to mark
the data as incomplete or unavailable, where appropriate. Finally, due to the nature of the program at
ACCESS, the charts that were reviewed only included
a checklist of information limited to each woman’s single cancer screening clinic visit, and thus we were unable
to perform both prior record review and follow up.
Conclusions
AA women are an understudied population and an
increasing ethnic minority in the United States. Information regarding their health-seeking behaviors and
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speciﬁc disease prevalence are currently lacking. Therefore, health care providers should be aware of the challenges that face them, particularly with regard to cervical
cancer screening and prevention. Additional studies targeting this demographic within the U.S. health system
should be done to facilitate preventative health care
and effective treatment strategies.
Acknowledgments
The authors thank Jessica Kowalski, Nadia Syed, and
Meredith Steih at the ACCESS clinic in Dearborn,
Michigan.
Author Disclosure Statement
No competing ﬁnancial interests exist.
Funding Information
No funding was received for this article.
References
1. World Health Organization. WHO Guidance Note: Comprehensive
Cervical Cancer Prevention and Control: A Healthier Future for Girls
and Women, 2013. Available at: https://apps.who.int/iris/bitstream/
handle/10665/78128/9789241505147_eng.pdf;jsessionid=190CCA77B
5D4F30AC224004BB7C460CF?sequence=3 Accessed December 2,
2020.
2. Bruni L, Albero G, Serrano B, et al. Human Papillomavirus and Related
Diseases in The World, 2016. Available at: https://www.hpvcentre.net/
statistics/reports/XWX.pdf Accessed December 2, 2020.
3. Jassim G, Obeid A, Al Nasheet HA. Knowledge, attitudes, and practices
regarding cervical cancer and screening among women visiting primary
care centres in Bahrain. BMC Public Health 2018;18:128.
4. Centers for Disease Control and Prevention. Cervical cancer: What are
the risk factors for cervical cancer? 2019. Available at: https://www.cdc
.gov/cancer/cervical/basic_info/risk_factors.htm Accessed December 2,
2020.
5. Abboud S, De Penning E, Brawner BM, Menon U, Glanz K, Sommers MS.
Cervical cancer screening among Arab women in the United States:
An integrative review. Oncol Nurs Forum 2017;44:E20–E33.
6. Ali S, Skirton H, Clark MT, Donaldson C. Integrative review of cervical
cancer screening in Western Asian and Middle Eastern Arab countries.
Nurs Health Sci 2017;19:414–426.
7. Sharma M, Seoud M, Kim JJ. Cost-effectiveness of increasing cervical
cancer screening coverage in the Middle East: An example from Lebanon.
Vaccine 2017;35:564–569.
8. Coughlin SS, Uhler RJ. Breast and cancer screening practices among
Hispanic women in the United States and Puerto Rico, 1998–1999. Prev
Med 2002;34:242–251.
9. Arab Community Center for Economic and Social Services. ACCESS
website. Available at: http://www.accesscommunity.org/ Accessed
December 2, 2020.
10. Clark TC, Endeshaw M, Senkomago V, Saraiya M. QuickStats: Percentage
of U.S. women aged 21–65 years who never had a Papanicolaou test (Pap
test), by place of birth and length of residence in the United States—
National Health Interview Survey, 2013 and 2015. MMWR Morb Mortal
Wkly Rep 2017;66:346.
11. Dallo FJ, Booza J, Nguyen ND. Functional limitations and nativity status
among older Arab, Asian, Black, Hispanic, and White Americans. J Immigr
Minor Health 2015;17:535–542.

278

12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
Personal Habits and Indoor Combustions: A Review of Human Carcinogens, Vol. 100E, 2012. Available at: https://publications.iarc.fr/122
Accessed December 2, 2020.
13. Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with
human cancers. J Natl Cancer Inst 2011;103:1827–1839.
14. World Health Organization. Prevalence of tobacco smoking: Agestandardized prevalence of current tobacco smoking among persons
aged 15 years and older (%), 2015: male, 2016. Available at: http://
gamapserver.who.int/gho/interactive_charts/tobacco/use/atlas.html
Accessed December 2, 2020.
15. Monsonego J, Cox JT, Behrens C, et al. Prevalence of high-risk human
papilloma virus genotypes and associated risk of cervical precancerous
lesions in a large U.S. screening population: Data from the ATHENA trial.
Gynecol Oncol 2015;137:47–54.
16. Knaul FM, Rodriguez NM, Arreola-Ornelas HA, Olson JR. Cervical cancer:
Lessons learned from neglected tropical diseases. Lancet Glob Health
2019;7:e299–e300.
17. The Catalan Institute of Oncology (ICO) and the International Agency for
Research on Cancer (IARC), Human Papillomavirus and Related Cancers
Fact Sheet, 2018. Available at: https://hpvcentre.net/statistics/reports/
USA_FS.pdf Accessed March 29, 2021.
18. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status
on cancer incidence and stage at diagnosis: Selected ﬁndings from the
surveillance epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009;20:417–435.
19. HPV Information Centre. Statistics, 2020. Available at: https://hpvcentre
.net/datastatistics.php Accessed December 2, 2020.
20. Ali MAM, Bedair RN, Abd El Atti RM. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation
Council countries: Prevalence, type-speciﬁc distribution, and correlation
with cervical cytology. Cancer Cytopathol 2019;127:567–577.
21. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of
precancer and cancer conferred by a negative human papillomavirus
test. J Natl Cancer Inst 2014;106:dju153.
22. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by
age, race/ethnicity, histological subtype, and stage at diagnosis in the
United States. Prev Med 2019;123:316–323.

Cite this article as: Shallal A, Abada E, Fehmi Z, Kamatham S, Trak J,
Fehmi O, Toma A, Farooqi S, Jang H, Kim S, Bandyopadhyay S, Zervos
M, Ali-Fehmi R (2021) Human papillomavirus infection and cervical
dysplasia in a subset of Arab American women, Women’s Health
Report 2:1, 273–278, DOI: 10.1089/whr.2020.0129.

Abbreviations Used
AA
ACCESS
AGC
ASC-H

¼
¼
¼
¼

ASC-US
BCCCP
CI
HPV
HSIL
LSIL
NHIS
NIL
OR
Pap
SEER
USD

¼
¼
¼
¼
¼
¼
¼
¼
¼
¼
¼
¼

Arab American
Arab-American Center for Economic and Social Services
atypical glandular cells
atypical squamous cells cannot rule out high-grade
squamous intraepithelial lesion
atypical cells of undetermined signiﬁcance
Breast and Cervical Cancer Control Program
conﬁdence interval
human papillomavirus
high-grade squamous intraepithelial lesion
low-grade squamous intraepithelial lesion
National Health Interview Survey
negative for intraepithelial lesion
odds ratio
Papanicolaou
surveillance, epidemiology, and end results
U.S. dollars

